Evaluation of the MicroTrak II HIV-1/HIV-2 recombinant antigen enzyme immunoassay.

Important note: Information in this article was accurate in 1994. The state of the art may have changed since the publication date.

Evaluation of the MicroTrak II HIV-1/HIV-2 recombinant antigen enzyme immunoassay.

Abstr Gen Meet Am Soc Microbiol. 1994;94:622 (abstract no. V-28). Unique Identifier : AIDSLINE ASM94/94313119
Kline R; Newhouse R; Granade T; Phillips S; Moss M; Quinn TC; Johns Hopkins Univ., Baltimore, MD.

Abstract: In a study, the reliability, sensitivity, and specificity of the MicroTrak II HIV-1/HIV-2 EIA (MT II) were compared to licensed EIAs and Western Blot (WB). 2490 sera from various populations in the US, Africa, and India were evaluated at 3 different sites using the MT II and licensed HIV-1/HIV-2 EIAs (Genetic Systems or Abbott). All repeatedly reactive sera were reconfirmed by WB for HIV-1. Sera that were indeterminate by WB, had discrepant results, or were previously known to be HIV-2 positive were retested using a licensed HIV-2 EIA (Genetic Systems). All reactive samples were confirmed by HIV-2 WB. Discrepant samples were also tested using a peptide assay (Select HIV). Final interpretation of serological results was primarily based on WB and, in some cases, RIPA, PCR, and culture. WB and other confirmatory testing identified 910 HIV-1/HIV-2 positive samples and 1580 HIV-1/HIV-2 negative samples. MT II detected all 910 positive samples for a sensitivity of 100% and the licensed HIV-1/HIV-2 EIAs detected 904 positive samples for a sensitivity of 99.3%. MT II characterized 1574 negative samples as negative for a specificity of 99.6% and the licensed EIAs detected 1565 negative samples as negative for a specificity of 99.1%. The 6 false positives by MT II were all sera from Africa. The MicroTrak II HIV-1/HIV-2 EIA is a reliable assay that has a slightly higher sensitivity and specificity compared to other licensed EIAs.

Keywords: Africa Blotting, Western/METHODS Comparative Study False Positive Reactions Human HIV Antigens/*BLOOD HIV Seropositivity/BLOOD/*DIAGNOSIS HIV-1/*ISOLATION & PURIF HIV-2/*ISOLATION & PURIF *Immunoenzyme Techniques India Predictive Value of Tests Sensitivity and Specificity United States ABSTRACT
941030
M94A0835

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1994. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1994. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .